Valuation in Life Sciences: A Practical Guide

by Boris Bogdan, Ralph Villiger

This book is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. It introduces the characteristics of drug and medical device development, explains how to translate these into the valuation, and provides valuable industry data. Special emphasis is put on the practicability of the proposed methods by including many hands-on examples, without compromising on realistic results.

Genres: Finance

272 pages, Kindle Edition

First published January 1, 2007

Reviews

[Serhii Kushchenko · Rating 4 out of 5]

The book is OK, but its authors could've done better. They could have presented the life sciences valuation methods in more understandable language.

If cash flow discounting is a new concept to you, consider postponing this read for a later time. Instead, delve into "Expectations Investing" by Mauboussin as a starting point.

This book may help create a biotech company valuation model to present to others. Its real options example is solid. It can serve as a good template.

Yet, when you wager your nest egg, you need a more robust approach. Relying solely on the methodologies outlined here for investment decisions is not a good idea. Predicting which drug candidates regulators will approve demands extensive expertise. You can't gain that expertise by reading just one small book.

[Nathan Lin · Rating 4 out of 5]

Worth Reading as an introduction book, especially the DCF part. But not very interested in the option evaluation. Moreover, contents are very basic.